Comparison
BPC-157 vs Curcumin
Side-by-side of BPC-157 and Curcumin. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
BPC-157
BPC-157 peptide profile: pentadecapeptide body protection compound 157. Preclinical data on tendon, gut healing, recovery. No human RCTs as of 2026.
Curcumin
Curcumin supplement guide: turmeric extract at 500-1000 mg/day, piperine and Meriva for absorption, evidence in joint inflammation and mood.
Effects at a glance
BPC-157
- •Preclinical models show accelerated tendon-to-bone and ligament healing after surgical or chemical injury
- •Rodent studies report mucosal protection and faster recovery from NSAID-induced and colitis-induced gut damage
- •Anecdotal human protocols use 250 to 500 mcg twice daily subcutaneously near the injury site
- •No completed phase II or III human RCTs as of 2026, so efficacy and long-term safety remain unestablished
- •Banned by WADA since 2022 under the S0 non-approved substances category for competitive athletes
- •Theoretical angiogenic concern means avoidance is prudent in active malignancy until human data exists
Curcumin
- •Reduces osteoarthritis knee pain comparable to ibuprofen at 1500 mg/day enhanced formulation
- •Modest antidepressant effect (SMD ~0.34) as monotherapy or SSRI adjunct in major depression
- •Standard curcumin has ~3% bioavailability; Meriva, BCM-95, Theracurmin shift absorption 5-30 fold
- •Inhibits NF-kB and COX-2; reduces hs-CRP, IL-6, TNF-alpha in chronic inflammation
- •Antiplatelet effect at higher doses; meaningful interaction with warfarin and DOACs
- •Iron chelation can contribute to deficiency in already-marginal patients
Side-by-side
| Attribute | BPC-157 | Curcumin |
|---|---|---|
| Category | peptide | natural |
| Also known as | Body Protection Compound-157, Pentadecapeptide BPC-157 | turmeric extract, diferuloylmethane |
| Half-life (hr) ↗ | 4 | 7 |
| Typical dose (mg) ↗ | 0.25 | 500 |
| Dosing frequency | daily (anecdotal protocols) | 1 to 2 times daily with meals |
| Routes | subcutaneous, intramuscular, oral | oral |
| Onset (hr) | - | 2 |
| Peak (hr) | - | 4 |
| Molecular weight | - | 368.38 |
| Molecular formula | C62H98N16O22 | C21H20O6 |
| Mechanism | Proposed upregulation of VEGFR2 and nitric oxide pathways, modulation of growth-hormone receptor expression, and stabilization of gut-brain axis signaling. Mechanism remains largely preclinical. | Inhibits NF-kB transcription factor, COX-2, and lipoxygenase; activates AMPK and Nrf2; modulates JAK-STAT and PI3K-Akt kinase signaling. Pleiotropic anti-inflammatory and antioxidant effects. |
| Legal status | Not FDA approved; research-use-only grey market; banned by WADA (2022) | Dietary supplement (global) |
| WADA status | banned | allowed |
| DEA / Rx | Not FDA approved; not scheduled; research-chemical status | Not scheduled |
| Pregnancy | Insufficient data | Culinary turmeric is safe; supplemental curcumin best avoided in pregnancy |
| CAS | 137525-51-0 | 458-37-7 |
| PubChem CID | 9941957 | 969516 |
| Wikidata | Q4835418 | Q312266 |
Safety profile
BPC-157
Common side effects
- injection-site irritation
- nausea
- headache (anecdotal)
Contraindications
- pregnancy
- active malignancy (theoretical angiogenic concern)
- no established safety profile in humans
Curcumin
Common side effects
- nausea
- diarrhea
- dyspepsia
- yellow stool (benign)
Contraindications
- active gallstones (curcumin stimulates gallbladder contraction)
- severe biliary obstruction
- scheduled elective surgery (discontinue 1-2 weeks prior)
Interactions
- warfarin and DOACs: additive antiplatelet and anticoagulant effects; meaningful bleeding risk at 1000+ mg/day(major)
- aspirin and NSAIDs: additive antiplatelet effect(moderate)
- tacrolimus and cyclosporine: CYP3A4 and P-gp modulation may alter drug levels(moderate)
- iron supplements: curcumin chelates iron; can contribute to deficiency in marginal patients(moderate)
- chemotherapy agents: potential interference with multiple agents; coordinate with oncology team(major)
Which Should You Take?
Curcumin comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. BPC-157 is the right call when one of the conditionals below applies.
- → If your priority is gut barrier and microbiome health, pick BPC-157.
- → If your priority is healthspan extension, pick Curcumin.
- → If your priority is joint health, pick Curcumin.
Edge case: If you want to avoid research-only / gray-market sourcing, Curcumin is the more accessible choice.
Default choice: Curcumin. Lower friction to source, and broader goal coverage. Reach for BPC-157 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between BPC-157 and Curcumin?
BPC-157 and Curcumin differ in category (peptide vs natural), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, BPC-157 or Curcumin?
BPC-157 half-life is 4 hours; Curcumin half-life is 7 hours.
Can you stack BPC-157 with Curcumin?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper